LoginSign Up
Acorda Therapeutics

Acorda Therapeutics

Acorda is a biotechnology company founded in 1995 by Ron Cohen and headquartered in Ardsley, New York developing and commercializing neurology therapies for Parkinson's disease, migraines, and multiple sclerosis.

Acroda Therapeutics is a biotechnology company based out of Ardsley, New York that was founded in 1995 by Ron Cohen. The company is working to develop and commercialize treatments for neurological disorders of the central nervous system such as multiple sclerosis, spinal cord injuries, and Parkinson's disease.

Acquisitions

Biotie Therapies

On January 19, 2016 Acorda Therapeutics acquired Biotie Therapies for $25.60 per share for a total of approximately $363 million. Acorda Therapeutics bought Biotie Therapies to acquire two of its drug candidates for the treatment of Parkinson's disease called Tozadenant and SYN120.

Timeline

People

Name
Role
Related Golden topics

Andrew Blight

Chief Scientific Officer

Andrew Hindman

Chief Business Officer

Burkhard Blank

Chief Medical Officer

David Lawrence

Chief Business Operations and Principal accounting Officer

Denise Duca

Executive Vice President

jane Wasman

President of International & General Counsel

Lauren Sabella

Chief Commercial Officer

Ron Cohen

Founder, President & CEO

Tierney Saccavino

Executive Vice President of Corporate Communications

Further reading

Title
Author
Link
Type

Acorda Therapeutics investor calls for company to explore sale

Greg Roumeliotis

News

Acorda Therapeutics stock rises on closure of FDA inspections

Uttara Choudhury

Web

What's Behind Acorda Therapeutics Crashing 24.5% Today -- The Motley Fool

Todd Campbell

News

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References